Overview of Pseudoproline Dipeptides
Pseudoproline dipeptides have emerged as a transformative tool in peptide synthesis, particularly in the context of Fmoc-based solid-phase peptide synthesis (SPPS). These specialized building blocks are designed to address challenges associated with peptide aggregation, poor solubility, and low coupling efficiency, which are common hurdles in synthesizing long, complex, or aggregation-prone peptides.
1. Introduction
Pseudoproline dipeptides are artificially created dipeptides derived from serine (Ser), threonine (Thr), or cysteine (Cys) residues, which are reversibly protected as oxazolidine (for Ser/Thr) or thiazolidine (for Cys) rings. These cyclic structures mimic the conformational properties of proline, hence the term “pseudoproline” (ψ-Pro). The introduction of pseudoproline dipeptides into peptide synthesis was pioneered to mitigate aggregation caused by β-sheet formation during SPPS, a process that often leads to incomplete coupling reactions and reduced yields.
Pseudoprolines were first described as a solubilizing, structure-disrupting protection technique by Wöhr and Mutter in 1995. Since then, their utility has been extensively validated in the synthesis of challenging peptides, including long peptides, cyclic peptides, and peptides with hydrophobic or aggregation-prone sequences.
2. Structure of Pseudoproline Dipeptides
Pseudoproline dipeptides consist of a dipeptide unit where the hydroxyl group of Ser/Thr or the thiol group of Cys reacts with an aldehyde or ketone (commonly acetone or formaldehyde) to form a five-membered oxazolidine or thiazolidine ring. This ring system incorporates the side chain and the α-amino group of the Ser/Thr/Cys residue, creating a proline-like structure.
• Oxazolidine-based pseudoprolines: Formed from Ser or Thr, these contain an oxygen atom in the ring (e.g., Fmoc-Xaa-Ser(ψMe,MePro)-OH or Fmoc-Xaa-Thr(ψMe,MePro)-OH).
• Thiazolidine-based pseudoprolines: Formed from Cys, these contain a sulfur atom (e.g., Fmoc-Xaa-Cys(ψDmp,HPro)-OH).
The pseudoproline moiety is stable under standard Fmoc SPPS conditions but can be cleaved with trifluoroacetic acid (TFA) during the final deprotection step, regenerating the native Ser, Thr, or Cys residue.
3. Synthesis of Pseudoproline Dipeptides
The preparation of pseudoproline dipeptides involves two primary strategies:
3.1 In Situ Acylation:
• Ser-, Thr-, or Cys-derived oxazolidines/thiazolidines are acylated using activated amino acid derivatives, such as acid fluorides or N-carboxyanhydrides (NCAs).
• This method is less common due to the low nucleophilicity of the pseudoproline nitrogen, which results in poor coupling yields.
3.2 Direct Insertion:
• The oxazolidine/thiazolidine ring is formed post-insertion into a dipeptide containing a C-terminal Ser, Thr, or Cys.
• For example, a dipeptide (e.g., Xaa-Ser) is reacted with dimethoxypropane or formaldehyde to form the pseudoproline ring, yielding a protected dipeptide suitable for SPPS.
• This approach is preferred for its higher efficiency and compatibility with automated synthesis.
Commercially available pseudoproline dipeptides are designed for seamless integration into automated SPPS protocols, ensuring ease of use and reproducibility.
4. Mechanism of Action
The primary role of pseudoproline dipeptides is to disrupt secondary structure formation, particularly β-sheet aggregates, during peptide synthesis. Their mechanism of action can be summarized as follows:
4.1 Conformational Disruption:
• The oxazolidine/thiazolidine ring imposes a “kink” in the peptide backbone, similar to proline’s cyclic structure.
• This kink favors cis-amide bond formation over trans, disrupting interchain hydrogen bonding responsible for β-sheet formation.
• By preventing aggregation, pseudoprolines enhance the solvation of the growing peptide chain, improving access to reactive sites.
4.2 Enhanced Solubility:
• Pseudoproline-containing peptides exhibit improved solubility in common SPPS solvents (e.g., DMF, NMP), facilitating coupling and deprotection reactions.
• This is particularly beneficial for hydrophobic or aggregation-prone sequences.
4.3 Improved Coupling Efficiency:
• By reducing aggregation, pseudoprolines ensure better exposure of the N-terminal amino group, leading to more efficient acylation.
• This results in higher yields and purer crude products, reducing the need for costly resynthesis.
4.4 Reversible Protection:
• The pseudoproline moiety is stable under weak acidic conditions (e.g., acetic acid/TFE/DCM) but is cleaved by TFA, restoring the native amino acid residue without introducing permanent modifications.
5. Applications in Peptide Synthesis
Pseudoproline dipeptides have found widespread application in the synthesis of peptides that are otherwise challenging to produce. Key applications include:
5.1 Synthesis of Long Peptides
Long peptides (>40 amino acids) are prone to aggregation, leading to incomplete couplings and low yields. Pseudoproline dipeptides have been instrumental in synthesizing peptides such as:
• Human Amylin (hAmylin): The 37-residue hAmylin and its 8-37 fragment were successfully synthesized with high yield using pseudoproline dipeptides, whereas standard Fmoc methods produced only traces of the desired product.
• RANTES (24-91): A 68-amino-acid chemokine with high aggregation propensity was synthesized efficiently using a combination of PEG-based ChemMatrix resin and pseudoproline dipeptides.
5.2 Synthesis of Cyclic Peptides
• Pseudoprolines facilitate cyclization by pre-organizing the linear peptide into a conformation conducive to ring closure.
• Their incorporation has been shown to increase cyclization yields and accelerate reaction rates, as seen in the synthesis of cyclic peptides like dendroamide A.
5.3 Synthesis of Aggregation-Prone Peptides
• Peptides with hydrophobic or β-sheet-forming sequences, such as those derived from membrane proteins, benefit significantly from pseudoproline incorporation.
• For example, a 54-amino-acid fragment of caveolin-1 was synthesized successfully by optimizing pseudoproline positioning, highlighting their role in tackling “difficult sequences.”
5.4 Convergent Peptide Synthesis
• Pseudoproline-containing peptide fragments exhibit improved solubility, facilitating purification and coupling in fragment condensation reactions.
• Their use minimizes racemization risks when coupling fragments with C-terminal pseudoprolines, enhancing the efficiency of convergent synthesis strategies.
5.5 Synthesis of Peptidomimetics
• Pseudoprolines serve as proline isosteres in peptidomimetic design, allowing modulation of conformational properties such as ring pucker and cis/trans amide bond ratios.
• They have potential applications in drug discovery by enabling the design of bioactive molecules with refined physicochemical properties.
6. Advantages of Pseudoproline Dipeptides
The adoption of pseudoproline dipeptides in SPPS has been driven by their numerous advantages:
6.1 Enhanced Synthetic Efficiency:
• Pseudoprolines can increase product yields by up to 10-fold in highly aggregated sequences, reducing the need for repeat syntheses.
• They improve acylation and deprotection kinetics, leading to more predictable reaction outcomes.
6.2 Ease of Use:
• Pseudoproline dipeptides are introduced using standard coupling methods, requiring no specialized equipment or protocols.
• They are compatible with automated peptide synthesizers, such as the Activo-P11 Peptide Synthesizer.
6.3 Versatility:
• Applicable to a wide range of peptides, including long peptides, cyclic peptides, and peptidomimetics.
• Suitable for both Ser/Thr- and Cys-containing sequences, with thiazolidine-based pseudoprolines expanding their utility.
6.4 Improved Product Quality:
• Incorporation of pseudoprolines results in purer crude products, simplifying HPLC purification and increasing product recovery.
• They minimize side reactions associated with aggregation, such as aspartimide formation (though see limitations below).
6.5 Reversible Modification:
• The pseudoproline moiety is temporary, ensuring no permanent alteration of the peptide sequence.
6.6 Solubility Enhancement:
• Peptides containing pseudoprolines exhibit improved solubility, which is critical for both synthesis and downstream applications like fragment condensation.
7. Limitations and Challenges
Despite their advantages, pseudoproline dipeptides are not without limitations, and their use requires careful consideration:
7.1 Steric Hindrance in Coupling:
• The oxazolidine/thiazolidine ring is sterically hindered, leading to low coupling yields when attaching amino acids to the pseudoproline N-terminus.
• This necessitates the use of preformed dipeptides rather than pseudoproline monomers.
7.2 Side Reactions:
• Recent studies have reported unexpected side reactions associated with pseudoproline dipeptides, particularly under harsh conditions like elevated temperature and pressure in flow peptide synthesis.
• For instance, aspartimide (Asi) formation has been observed to be catalyzed by pseudoproline moieties in some cases, contrary to their intended role in suppressing such side reactions.
• Imine derivatives of the pseudoproline moiety and multiple products with identical masses but different retention times have also been noted, complicating purification.
7.3 Mass Spectrometry Artifacts:
• The incorporation of pseudoproline dipeptides can lead to higher-than-expected molecular weights in mass spectrometry, potentially due to ion entanglement or stabilization effects. This requires careful validation, such as NMR analysis of peptide fragments, to confirm the integrity of the product.
7.4 Empirical Guidelines for Placement:
• Optimal pseudoproline placement (e.g., every 5-6 residues, at least 2 residues from another pseudoproline or proline, before hydrophobic regions) is based on empirical guidelines rather than universal rules, requiring trial and error for new sequences.
• Incorrect positioning can reduce their effectiveness or introduce synthetic complications.
7.5 Cost and Availability:
• While pseudoproline dipeptides are commercially available, their cost can be a limiting factor for large-scale syntheses or resource-constrained laboratories.
• The range of available pseudoproline dipeptides, while extensive, may not cover all possible Xaa-Ser/Thr/Cys combinations, necessitating custom synthesis in some cases.
7.6 Limited Stability Under Certain Conditions:
• Although pseudoprolines are stable under weak acidic conditions, their behavior under non-standard conditions (e.g., high temperature, prolonged TFA exposure) can lead to ring opening or other side reactions, affecting product consistency.
8. Practical Guidelines for Use
To maximize the benefits of pseudoproline dipeptides, the following practical guidelines are recommended based on literature and industry experience:
8.1 Positioning:
• Space pseudoprolines 5-6 residues apart to optimize disruption of secondary structures.
• Maintain a minimum separation of 2 residues between pseudoprolines or between a pseudoproline and a proline.
• Place pseudoprolines before hydrophobic regions to enhance solubility and coupling efficiency.
8.2 Coupling Conditions:
• Use standard Fmoc SPPS coupling reagents (e.g., HBTU, DIC/HOBt) for pseudoproline incorporation.
• Consider microwave-assisted coupling to accelerate reactions, particularly for long peptides.
8.3 Resin Selection:
• Pair pseudoproline dipeptides with low-aggregation resins like 2-chlorotrityl or ChemMatrix for optimal results.
• PEG-based resins are particularly effective for synthesizing complex peptides in combination with pseudoprolines.
8.4 Cleavage and Deprotection:
• Use standard TFA-based cleavage cocktails to remove the pseudoproline moiety and regenerate the native residue.
• For fragment synthesis, cleave peptides from resins like 2-chlorotrityl or Sieber with weak acids (e.g., 1% TFA) to retain the pseudoproline for enhanced solubility during condensation.
8.5 Monitoring and Validation:
• Perform regular mass spectrometry checks during synthesis to monitor progress, but be aware of potential mass artifacts.
• Validate final products with NMR or HPLC to confirm the absence of side products like aspartimides.
9. Case Studies
9.1 Human Islet Amyloid Polypeptide (hIAPP)
• Challenge: hIAPP is a 37-residue peptide prone to amyloidogenic aggregation, making its synthesis via standard Fmoc SPPS nearly impossible.
• Solution: Incorporation of pseudoproline dipeptides enabled the synthesis of hIAPP and its 8-37 fragment with high yield and purity. The crude product was pure enough for disulfide bond formation by air oxidation.
• Outcome: Demonstrated the power of pseudoprolines in tackling highly aggregation-prone sequences.
9.2 Caveolin-1 Fragment
• Challenge: A 54-amino-acid fragment of caveolin-1 encompassing the intramembrane domain was difficult to synthesize due to aggregation.
• Solution: Strategic incorporation of pseudoproline dipeptides, with slight modifications in positioning, overcame aggregation issues and enabled successful synthesis.
• Outcome: Highlighted the importance of optimizing pseudoproline placement for specific sequences.
9.3 RANTES (24-91)
• Challenge: This 68-amino-acid chemokine has a high propensity for aggregation, complicating SPPS.
• Solution: The use of ChemMatrix resin combined with pseudoproline dipeptides facilitated efficient synthesis, overcoming aggregation barriers.
• Outcome: Validated the synergy between advanced resins and pseudoprolines for complex peptide synthesis.
10. Future Prospects
The success of pseudoproline dipeptides in peptide synthesis opens several avenues for future research and development:
10.1 Expanded Chemical Diversity:
• Developing new pseudoproline derivatives with tailored heteroatoms (e.g., silicon, selenium) could further modulate conformational properties and enhance their utility in peptidomimetic design.
10.2 Automation and High-Throughput Synthesis:
• Integrating pseudoproline dipeptides into fully automated, high-throughput SPPS platforms could streamline the production of complex peptides for therapeutic and research applications.
10.3 Mitigation of Side Reactions:
• Further studies are needed to understand and prevent side reactions like aspartimide formation under specific conditions, potentially through modified pseudoproline structures or optimized synthesis protocols.
10.4 Application in Drug Discovery:
• The use of pseudoprolines as proline isosteres in small-molecule drug design holds promise for creating bioactive molecules with improved pharmacokinetic profiles.
• Their role in stabilizing peptide-based therapeutics, such as those targeting membrane proteins, warrants further exploration.
10.5 Sustainability and Cost Reduction:
• Advances in synthetic methods could reduce the cost of pseudoproline dipeptides, making them more accessible for large-scale peptide production.
10.6 Combination with Emerging Technologies:
• Pairing pseudoproline dipeptides with novel resin technologies or flow chemistry, could push the boundaries of peptide synthesis, enabling the production of previously inaccessible molecules.
Pseudoproline dipeptides represent a cornerstone of modern peptide synthesis, offering a robust solution to the challenges of aggregation, solubility, and coupling efficiency in Fmoc SPPS. Their ability to disrupt secondary structures, enhance solubility, and improve yields has made them indispensable for synthesizing long, cyclic, and aggregation-prone peptides. While limitations such as steric hindrance, potential side reactions, and empirical positioning guidelines exist, these can be managed through careful planning and optimization.
The versatility of pseudoproline dipeptides, coupled with their ease of use and compatibility with standard SPPS protocols, ensures their continued relevance in both academic research and industrial applications. As peptide-based therapeutics and peptidomimetics gain prominence in drug discovery, pseudoproline dipeptides are poised to play a pivotal role in unlocking the full potential of these molecules. Ongoing research and innovation will likely further refine their utility, cementing their status as one of the most powerful tools in peptide chemistry.
ChemPep: Powering Peptide Success with Premium Pseudoproline Dipeptides!
Unlock superior performance in peptide synthesis with ChemPep’s premium-grade Pseudoproline Dipeptides. Specially designed to overcome challenges in solid-phase peptide synthesis (SPPS), our pseudoproline building blocks help eliminate aggregation, enhance chain solvation, and improve the purity and yield of even the most difficult peptide sequences.
• Fmoc-protected and ready-to-use
• Ideal for long, hydrophobic, or aggregation-prone peptides
• Compatible with standard SPPS protocols and reagents
• Cleaved cleanly under standard acidic conditions (TFA)
• Available in research and bulk quantities
Discover our wide selection of oxazolidine and thiazolidine-based dipeptides, including derivatives of Serine, Threonine, and Cysteine – essential tools for researchers, biotech firms, and pharmaceutical developers.
Serine-containing Pseudoproline Dipeptides
References
1. Mutter, Manfred (2013). “Four Decades, Four Places and Four Concepts”. CHIMIA. 67 (12): 868–873.
2. Mutter, M., Vuilleumier, S., Angew. Chem., (1989) 101, p.551; Angew. Chem. Int. Ed. Engl., (1989) 28, p.535
3. Toniolo. C, Bonora. G. M., Multer. M., Pillai. V.N.R., Makromol. Chem. (1981) 182. p.1997
4. Mutter. M., Pillai. V. N. R., Anzinger. H., Bayer, E., Toniolo, C, In Peptides (1980) Brunfeldt. K. Ed., Scriptor: Copenhagen. (1981) pp.660
5. Johnson, T., Quibell. M., Sheppard, R. C., J. Pept. Sci. (1995) 1. p.11
6. Wöhr. T., Wahl. E., Nefzi. A., Rohwedder. S., Sato. T., Sun, X., Mutter. M . J. Am. Chem. Soc. (1996) 118, p.9218
7. Dumy, P., Keller. M., Ryan, D. E., Rohwedder.B., Wöhr. T., Muller, M. J. Am. Chem. Soc., (1997) 119. p.918
8. Keller, M., Sager. C, Dumy, P., Schutkowski. M., Fischer. G. S., Mutter. M., J. Am. Chem. Soc. (1998) 120, p.2714
9. Mutter, M., Nafzi. A., Sato. T., Sun, X., Wahl. E, Wöhr,T. Peplide Res. (1995) 8. 145.
10. Nefzi. A., Schenk K., Mutter. M . Protein Pept Lett. (1994) 1, p.66
11. Fülop F., Mattinen J., Pihlaja K., Tetrahedron (1990) 46, p.6545
12. Kallen RG., J. Am. Chem. Soc., (1971) 93, p.6236
13. P. White, et al. (2004) J. Pept. Sci. 10, 18
14. Balbach J, Schmid FX. (2000). Proline isomerization and its catalysis in protein folding. In Mechanisms of Protein Folding 2nd ed. Editor RH Pain. Oxford University Press.
15. T. Haack & M. Mutter (1992) Tetrahedron Lett. 33, 1589
16. W.R.Sampson, et al. (1999) J. Pept. Sci. 5, 403
17. P. White, et al. (2003) Biopolymers, 71, 338.P156
18. Cocchi F. et al., Science 270:1811–1815, 1995
19. Proost P. et al., J Biol Chem, Vol. 273, Issue 13, 7222-7227, 1998
20. Nardesse, V.;Longhi, R. Nat Struct Biol 2001, 8, 611-615.
21. Fayna García-Martín et al., Biopolymers (Pept Sci) 84: 566-575, 2006
22. D.A.Senko; N.D.Timofeev1; I. E. Kasheverov; I.A.Ivanov. Scope and limitations of pseudoprolines as individual amino acids in peptide synthesis. Amino Acids. 2021, 53, 665.
23. S.R. Manne; A. Chakraborty; K. Rustler; T. Bruckdorfer; B.G. de la Torre; F. Albericio. Solid-Phase Synthesis of an “Inaccesible” hGH-Derived Peptide Using a Pseudoproline Monomer and SIT-Protection for Cysteine. ACS Omega 2022, 7, 28487-28492.
24. S.R.Manne, K. Rustler, T, Bruckdorfer, B.G. de la Torre; F. Albericio. Incorporation of pseudoproline monomer (Fmoc-Thr[ΨMe,Mepro]–OH) facilitates efficient solid-phase synthesis of difficult peptides. Tetrahedron Lett. 2022, 115, 154301.
25. Sz. Szaniszló, K. Ferentzi, A. Perczel, and V. Farkas, “Improved Acylation of Pseudoproline: Masked Threonine in Flow Peptide Chemistry,” Org Process Res Dev, vol. 27, no. 6, pp. 1053–1060, Jun. 2023.
